High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity

Annals of Oncology

Volumn 11, Issue 4, 2000, Pages 427-434

  Decatris, M P ^a   Wilkinson, P M ^a   Welch, R S ^a   Metzner, M ^a   Morgenstern, G R ^a   Dougall, M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

High dose chemotherapy; Poor prognosis germ cell tumours

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; HUMAN; MALE; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034087569     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008393512723     Document Type: Article

References (25)

1. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
2. The International Germ-Cell Cancer Collaborative Group. International germ-cell consensus classification: A prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 1997; 15: 594-603.
3. Toner GC, Motzer RJ. Poor prognosis germ-cell tumours: Current status and future directions. Semin Oncol 1998; 25: 194-202.
4. Siegert W, Beyer J. Germ-cell tumours: Dose-intensive therapy. Semin Oncol 1998; 25: 215-23.
5. Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ-cell tumours. German Testicular Cancer Study Group. Semin Oncol 1998; 25: 24-32.
6. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ-cell tumors. Early intervention is better tolerated. Cancer 1992: 69; 550-6.
7. Mead GM. International consensus prognostic classification for metastatic germ-cell tumours treated with platinum based chemotherapy; final report of the International Germ-Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 1995; 14: 235 (Abstr 615).
8. Dodd PM, Motzer RJ, Bajorin DF. Poor-risk germ-cell tumours. Recent developments. Urol Clin North Am 1998; 25: 485-93.
9. Bokemeyer C, Harstrick A, Metzner B et al. Sequential high-dose VIP-chemotherapy plus peripheral stem-cell (PBSC) support for advanced germ-cell cancer. Ann Oncol 1996; 7: 55 (Abstr 259).
10. Bower M, Holden L, Rustin G, Newlands ES. POMB/ACE chemotherapy for advanced non-seminomatous germ-cell tumours in men. Proc Am Soc Clin Oncol 1997; 16: 319 (Abstr 1136).
11. Horwich A, Mason M, Fossa SD et al. Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ-cell tumours. Proc Am Soc Clin Oncol 1997; 16: 319 (Abstr 1137).
12. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic non-seminomatous germ-cell tumour: A Randomised Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701.
13. Germa-Lluch J, Garcia del Muro X, Tabernero J et al. BOMP/ EPI intensive alternating chemotherapy for IGCCCG poor-prognosis germ-cell tumours: The Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 1999; 10: 289-93.
14. Motzer, RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumours. J Natl Cancer Inst 1993; 85: 1828-35.
15. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomised comparison. J Clin Oncol 1995; 13: 1328-35.
16. Mead, GM, Stenning SP, Parkinson MC et al. The Second Medical Research Council study of prognostic factors in non-seminomatous germ-cell tumours. Medical Research Council Testicular Tumour Working Party [published erratum appeared in J Clin Oncol 1992; 10 (5): 867]. J. Clin Oncol 1992; 10: 85-94.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
18. Motzer, RJ, Mazumdar M. Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumours. J Clin Oncol 1997; 15: 2546-52.
19. Chevreau, C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ-cell tumours. Preliminary results of a French randomised trial. Eur Urol 1993; 23: 213-7.
20. Nichols, CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ-cell tumours: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-72.
21. Nichols, C, Loehrer P, Einhorn L. Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide, ifosfamide and cisplatin in advanced stage germ-cell tumours: An Intergroup trial. Proc Am Soc Clin Oncol 1995; 14: 239 (Abstr).
22. Bosl GJ, Geller NL, Cirrincione C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403-7.
23. Toner, GC, Geller NL, Lin SY, Bosl GJ. Extragonadal and poor risk nonseminomatous germ-cell tumours. Survival and prognostic features. Cancer 1991; 67: 2049-57.
24. Bajorin, D, Katz A, Chan E et al. Comparison of criteria for assigning germ cell tumour patients to 'good risk' and 'poor risk' studies. J Clin Oncol 1988; 6: 786-92.
25. Anthoney, DA, Kaye SB. Treatment for poor prognosis metastatic germ-cell tumours: Much heat but, as yet, little light. Ann Oncol 1999; 10: 255-8.